ID: ALA3400488

Max Phase: Preclinical

Molecular Formula: C15H12ClN3OS

Molecular Weight: 317.80

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1ccc2c(=O)nc(N(C)c3ccc(Cl)cc3)sc2n1

Standard InChI:  InChI=1S/C15H12ClN3OS/c1-9-3-8-12-13(20)18-15(21-14(12)17-9)19(2)11-6-4-10(16)5-7-11/h3-8H,1-2H3

Standard InChI Key:  NTKMBPPCQCBAMV-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 317.80Molecular Weight (Monoisotopic): 317.0390AlogP: 3.78#Rotatable Bonds: 2
Polar Surface Area: 46.09Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 0.79CX LogP: 3.68CX LogD: 3.68
Aromatic Rings: 3Heavy Atoms: 21QED Weighted: 0.72Np Likeness Score: -1.57

References

1. Inami H, Shishikura J, Yasunaga T, Ohno K, Yamashita H, Kato K, Sakamoto S..  (2015)  Synthesis, structure-activity relationships, and anticonvulsant activities of 2-amino-4H-pyrido[3,2-e][1,3]thiazin-4-one derivatives as orally active AMPA receptor antagonists.,  23  (8): [PMID:25792143] [10.1016/j.bmc.2015.02.033]

Source